Publicaciones en colaboración con investigadores/as de University of North Carolina at Chapel Hill (9)

2023

  1. Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer (npj Breast Cancer, (2021), 7, 1, (1), 10.1038/s41523-020-00208-2)

    npj Breast Cancer

2021

  1. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease

    Journal of Clinical Investigation, Vol. 130, Núm. 9, pp. 4871-4887

2019

  1. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

    Frontiers in Oncology, Vol. 9, Núm. APR

2017

  1. A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse

    Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3035-3044

  2. Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer

    Cancer Research, Vol. 77, Núm. 9, pp. 2213-2221

2015

  1. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

    Annals of Oncology, Vol. 26, Núm. 7, pp. 1280-1291

2014

  1. Predicting response and survival in chemotherapy-treated triple-negative breast cancer

    British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541

2009

  1. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics

    Cancer Research, Vol. 69, Núm. 10, pp. 4116-4124